SPRIM Global Investments and OneIM Launch $300 Million Joint Venture to Accelerate Clinical Study Financing

A New Era for Clinical Study Funding

In a significant development for the biopharmaceutical sector, SPRIM Global Investments (SGI), a leading investment firm in the life sciences industry, has joined forces with One Investment Management (OneIM) to establish a $300 million joint venture. This strategic partnership, announced on March 11, 2025, aims to enhance the financing of crucial clinical studies that are essential for the development of innovative medical treatments.

The Venture's Purpose

The joint venture is set to accelerate funding for clinical studies ranging from Phase 1 to Phase 3, focusing particularly on supporting breakthrough therapies. The collaboration will enhance TrialCap, SGI's specialized funding platform, which has garnered attention for its groundbreaking financing solutions tailored for biotech and medtech firms.

Michael Shleifer, co-founder and Managing Partner of SGI, expressed enthusiasm for this new direction: "Our mission is to eliminate the financial barriers that hinder biotech and medtech companies from focusing on research and development. This partnership with OneIM will significantly expand our ability to provide essential financing solutions that stimulate innovation in the life sciences."

TrialCap's Role

TrialCap serves as a revolutionary financing platform that caters to biotech companies aiming to fast-track their clinical trials. Leveraging over two decades of industry expertise, it offers flexible financial support to propel clinical studies and expedite the introduction of transformative therapies into the market.

Matt Ross, a Partner at OneIM, shared his perspective on the vast potential in the life sciences sector. He remarked, "We see enormous opportunities within the biopharmaceutical industry and are excited to team up with SGI, a company with a proven track record and deep connectivity in the healthcare ecosystem. We look forward to collaborating with Michael and his team to accelerate the growth of this platform."

The Companies Behind the Venture

Founded in 2008, SPRIM Global Investments specializes in clinical-stage life sciences and provides substantial support to promising biotech companies worldwide. Its innovative investment model is designed to provide impactful financing that assists in advancing clinical studies and developing life-changing treatments.

On the other hand, OneIM is a global alternative investment manager that invests across various asset classes and sectors. Founded in 2022, the firm has quickly established itself with approximately $7 billion in assets under management, focusing on creating long-term value through strategic partnerships and utilizing its expertise to achieve differentiated risk-adjusted returns. The firm operates from offices in major financial hubs, including Abu Dhabi, London, Tokyo, and New York.

Conclusion

The collaboration between SPRIM Global Investments and OneIM marks a pivotal moment in the biotech field, where financing challenges can often impede innovation. This joint venture promises to pave the way for more streamlined funding processes in clinical studies, ultimately leading to faster development and delivery of groundbreaking therapies to the market. By removing financial hurdles and enhancing support for clinical trials, SGI and OneIM are set to make a lasting impact on the biopharmaceutical landscape.